fda compounding semaglutide warning september 2025 issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA Adds New Warning for

The session, Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor TriagonistObesity, NAFLD, and T2D Phase 2 Trial Results , can be viewed on-demand by registered meeting participants at ADA2023.org

Sanofi has no disclosed triple agonist in its public pipeline

Tirzepatide generally produces greater average weight loss in clinical studies, while semaglutide has a longer history of use and remains a popular option for many patients

Pavlovic N, Tcheugui JE, &Ndumele CE

Both drugs are synthetic versions of those hormones, designed to activate specific receptors in the body

If your math shows 5.7 doses, the tool will display 5